site stats

Poor progression-free survival

WebDec 6, 2024 · Survival of patients with breast cancer has increased in recent years due to the improvement of systemic treatment options. Nevertheless, the occurrence of brain metastases is associated with a poor prognosis. Moreover, most drugs do not penetrate the central nervous system because of the blood–brain barrier. Thus, confirmed intracranial … WebProgression-free survival refers to the time from randomisation or initiation of treatment to the occurrence of disease progression or death. Disease progression is defined by the Response Evaluation Criteria in Solid Tumors as an increase in the sum of maximum …

Pre-existing hypertension is associated with poor progression-free ...

WebFeb 9, 2015 · Purpose To conduct analyses exploring trial-level and patient-level associations between overall response rate (ORR), progression-free survival (PFS), and overall survival (OS) in advanced non–small-cell lung cancer (NSCLC) trials. Methods We identified 14 trials (N = 12,567) submitted to US Food and Drug Administration since 2003 … WebApr 20, 2024 · Approximately 31% of patients diagnosed with multiple myeloma (MM) have pre-existing hypertension, but its effects on patient survival have not been investigated. … the origin of millet https://americanffc.org

(PDF) Progression-Free Survival Prediction in Patients with ...

WebNov 30, 2024 · Objectives The majority of patients with head and neck cancer (HNC) come to the hospital at advanced stages. This research was conducted to determine the mortality, 2-year progression-free survival (PFS) and factors that influenced PFS of HNC patients. Methods A retrospective cohort study was conducted among locally advanced HNC … WebProgression free survival (PFS) was similar between non-diabetics and diabetics on Met. Both groups had a significantly higher PFS than diabetics without Met. The article does … WebApr 6, 2024 · miR-25 overexpression in CD138+ plasma cells is associated with poor overall and progression-free survival. Kaplan–Meier survival curves for A overall survival (OS) and B progression-free survival (PFS) of the screening cohort, and for C OS of the MMRF CoMMpass validation cohort, according to CD138+ miR-25 expression. the origin of mohism

What Survival Rate Really Means With Ca…

Category:P53 Is Involved in Sunitinib Resistance and Poor Progression-free ...

Tags:Poor progression-free survival

Poor progression-free survival

Overall Response Rate, Progression-Free Survival, and Overall Survival …

WebBy contrast, the progression-free survival at 3 years was higher than 90% and thus similar to unselected patients. Accordingly, addition of rituximab to improve the presumably poor progression-free survival did not show any efficacy over standard treatment with BEACOPP escalated followed by radiotherapy to PET-positive residual disease. WebFeb 27, 2012 · The last few years have seen an increase in the number of randomized controlled trials (RCTs) of new agents in metastatic solid tumors using progression-free survival (PFS) as the primary end point. Some trials showing improvement in PFS, without a corresponding increase in overall survival (OS), have led to approval of new drugs and/or …

Poor progression-free survival

Did you know?

WebWe evaluated early disease progression and its impact on overall survival (OS) in previously untreated follicular lymphoma patients in GALLIUM (clinicaltrials.gov identifier: 01332968), and investigated the effect on early disease progression of the two randomization arms: obinutuzumab-based versus rituximab-based immunochemotherapy. Cause-specific Cox … WebFeb 27, 2012 · The last few years have seen an increase in the number of randomized controlled trials (RCTs) of new agents in metastatic solid tumors using progression-free …

WebMay 20, 2024 · Progression-free survival (PFS) and overall survival (OS) were determined by Kaplan–Meier method. The median OS and PFS after first-line treatment were 9.7 and 4.0 years, respectively. WebNivolumab, an anti–programmed death 1 antibody, has been approved for the treatment of NSCLC. Although nivolumab improves overall survival (OS) more than docetaxel when …

WebThe timing for long-term follow-up was not prespecified and the analysis was descriptive in nature. Ibrutinib was superior to ofatumumab in difficult-to-treat patients with relapsed or refractory CLL or SLL, as measured by progression-free survival, overall survival, and response. 2. Byrd, et al. N Engl J Med. 2014;371 (3):213-223. WebApr 11, 2024 · To establish a novel model using radiomics analysis of pre-treatment and post-treatment magnetic resonance (MR) images for prediction of progression-free …

WebApr 9, 2024 · Non-small cell cancer (NSCLC) has been identified with a great variation of mutations that can be surveyed during disease progression. The aim of the study was to identify and monitor lung cancer-specific mutations incidence in cell-free DNA as well as overall plasma cell-free DNA load by means of targeted next-generation sequencing. …

WebThe patients were divided into high and low sIL-2R groups based on the median of sIL-2R levels at pretreatment. Progression-free survival (PFS) and overall survival (OS) of patients in the high and low sIL-2R groups were compared. The Kaplan–Meier curves of PFS and OS were evaluated using the log-rank test. the origin of moneyWebWe investigated the relationship between progression-free survival (PFS) and patient characteristics. Results: In both univariate and multivariate analysis, performance status … the origin of modern chemistryWebSep 17, 2024 · We aim to analyze progression-free survival at 24 months (PFS24) and subsequent overall survival (OS) in a large-scale multicenter cohort of patients. 1790 patients were included from the China ... the origin of monotheismWebMar 28, 2024 · Among patients with tumors harboring mESR1, elacestrant was associated with a 45% reduction in the risk of progression or death compared with standard therapy.In this subgroup, the median PFS was 3.79 months with elacestrant and 1.87 months with standard endocrine therapy (HR, 0.54; p =.0005). Elacestrant was associated with a higher … the origin of moralityWebProgression-free survival as a potential surrogate for overall survival in metastatic breast cancer Catherine Beauchemin,1 Dan Cooper,2 Marie-Ève Lapierre,1 Louise Yelle,3 Jean ... the origin of mooncakesthe origin of negro slavery eric williamsWebMethods Forty-three nasopharyngeal carcinoma patients less than 19 years old were recruited between April 2010 and April 2016. All patients were treated with IMRT (total dose 61.2-76 Gy) combined with cisplatin based chemotherapy. The Kaplan-Meier test was used to calculate overall survival (OS) and progression-free survival (PFS). the origin of moses